Background: Cytomegalovirus (CMV) results in significant morbidity and mortality in Human Immunodeficiency Virus (HIV)-infected individuals. There is paucity of literature on paediatric CMV disease, especially from developing countries. Methods: A retrospective review of records of all HIV-infected children with evidence of CMV disease was done. Results: A total of 15 children were found to have CMV disease (retinitis in all, pneumonia in two and invasive gastrointestinal disease in one). Median CD4þ T cell count and percentage at diagnosis of CMV disease was 64.5 cells/ml and 3.6%, respectively. Intravenous ganciclovir was used in patients with active CMV disease. Of the 15 children, three died while two were lost to follow-up. Symptomatic patients had poor visual outcome and almost all children who were diagnosed on active screening attained normal vision. Conclusion: Retinitis is the most common CMV disease in HIV-infected children. Early detection by active screening and initiation of systemic ganciclovir reduces the morbidity.
be associated with immune reconstitution inflammatory syndrome (IRIS) and has a propensity to cause immune recovery uveitis [9] . There is paucity of literature on paediatric CMV disease, especially from developing countries. We report our experience of CMV disease in children living with HIV infection from a tertiary care referral centre of North India over the past 23 years.
P A T I E N T S A N D M E T H O D S
We reviewed the case records of all HIV-infected children being followed up at the Pediatric Immunodeficiency Clinic at Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India during the period from January 1994 to December 2016. This institute is a federally funded not-for-profit medical school in North India. The demographic and clinical data of patients diagnosed with CMV disease were recorded on a predesigned proforma.
The diagnosis of HIV infection in children >18 months of age was established by detection of HIV antibodies by Enzyme-Linked Immuno-Sorbent Assay. In children <18 months of age, diagnosis was confirmed by positive HIV DNA polymerase chain reaction (PCR) using dried blood spot on two separate occasions. This was in consonance with guidelines enunciated by the National AIDS Control Organization of India.
In our clinic, all newly diagnosed children with HIV infection undergo a detailed ophthalmological examination. Serum titres of anti-CMV IgM antibody are also assayed. In children with evidence of CMV disease on eye examination or positive IgM CMV antibody titres, the CMV DNA PCR test was also carried out. However, CMV DNA PCR test was not readily available in the institute before 2010 and hence could not be done in all patients. CMV viral load could not be performed because of resource constraints.
The diagnosis of CMV retinitis was based on typical ophthalmological findings-haemorrhagic or exudative full thickness retinitis or retinal necrosis (Figures 1 and 2 ). CMV pneumonia was presumed in the presence of radiological finding of interstitial pneumonia and evidence of CMV retinitis along with positive IgM CMV serology or positive CMV DNA PCR in serum. Children with evidence of two or more organ system involvement were labelled to have disseminated CMV disease.
The criteria used to define unmasking CMV IRIS included the following: (1) initiation of ART without screening for CMV retinitis; (2) symptoms in the form of decreased visual acuity; (3) indirect ophthalmoscopy finding suggestive of vitreous inflammation; and (4) sudden rise in CD4þ T cell counts from the baseline after initiating ART [10, 11] .
Treatment of CMV infection was based on standard guidelines [12] . No treatment was offered if there was evidence of healed retinitis. Intravenous ganciclovir (5 mg/kg/dose twice daily) for at least 2 weeks was used for induction, and the duration was prolonged in patients with poor response or delayed remission. Foscarnet is not readily available at our centre and could be used in only one patient. Additional intravitreal ganciclovir (given biweekly) was used in patients with severe disease as assessed by the ophthalmologists. Intravitreal therapy alone was not used in any patient. All patients received maintenance therapy with either oral ganciclovir or valganciclovir for at least 6 months. Maintenance therapy was discontinued only if retinitis had healed (Figures 2B) and the CD4þ T cell counts were stable (>100 cells/ml in children !6 years and >15% of all lymphocytes in children <6 years of age) for at least 6 months.
R E S U L T S
During the study period, 840 children were diagnosed to have HIV infection. Of these, 15 were found to have CMV retinitis. In addition to retinitis, two patients also had CMV pneumonitis and one had invasive gastrointestinal disease because of CMV (Tables 1 and 2) .
Eleven children (74%) were diagnosed to have CMV retinitis on initial screening (eight active and three inactive diseases). One patient was referred to our centre in view of failure of first-line ART, which he had received for 10 years. Active CMV retinitis was found on screening in this child. Unmasking CMV IRIS was detected in 3 of 15 patients (20%). These patients had been initiated on ART elsewhere and pre-ART ophthalmological screening had not been carried out. They were referred to our institute when they reported visual symptoms. Median time for detection of IRIS after initiating of ART was 4 weeks (3-8 weeks). Six of these 15 patients (40%) reported impaired vision at presentation, while the remaining nine children (60%) denied any ocular symptoms. Two patients had retinal detachment at the time of diagnosis (Nos. 7 and 13).
Median CD4þ T cell count and CD4þ T cell percentage at diagnosis of CMV disease (in patients without IRIS) was 64.5 cells/ml (interquartile range, IQR: 38.75-158.25) and 3.6% (IQR: 1.9-5.27) respectively. CD4þ T cell counts at the time of diagnosis of IRIS in three children were 559 cells/ml (26%), 390 cells/ml (15%) and 249 cells/ml (12.5%), respectively, while their CD4þ T cell counts before initiating ART was 145 cells/ml (6.7%), 48 cells/ml (2%) and 134 cells/ml (7.7%), respectively, with a median rise in CD4þ T cell count of 342 cells/ml.
Twelve patients were treated for active CMV disease (intravenous ganciclovir, as induction therapy), and in the remaining three children, no treatment was considered necessary because of healed retinitis. Four patients also received intravitreal ganciclovir biweekly (11, 10, 5 and 3 injections, respectively). Intravenous foscarnet was given to one patient (No. 6). The duration of induction therapy was determined by evidence of healing on fundus evaluation. Induction therapy was continued till there was objective evidence of healing on fundus evaluation, and this ranged from 2 weeks to 3 months. Two children died during induction phase (Nos. 11 and 12).
Remaining 10 patients received maintenance therapy that was continued till immune reconstitution (range 2 months to 54 months). Adverse effects of ganciclovir included thrombocytopenia (two patients) and neutropenia (one patient). These were transient and responded to temporary discontinuation of ganciclovir.
Additional immunosuppressive therapy was used in children with IRIS. One child (No. 13) had rapidly deteriorating visual acuity and received salvage therapy with three doses of methyl prednisolone followed by oral prednisolone. Another patient (No. 8) received oral prednisolone (1 mg/kg/day) for 2 weeks that was tapered over the next 2 months. ART was not discontinued in any patient. ART (usually with zidovudine, lamivudine and nevirapine) was initiated 2 weeks after starting induction therapy for CMV. Second-line drugs (abacavir, lamivudine and lopinavir/ritonavir) were initiated in patient nos. 6 and 8, who had clinical, virological and immunological failure following the first-line therapy.
Of the 15 children in our cohort, three died while two were lost to follow-up. Patient no. 12 presented at 10 months of age with blood in stools and intestinal obstruction. She underwent emergency exploratory laparotomy following intestinal perforation, but succumbed to her illness on Day 3 of surgery. Histopathology examination of resected large bowel suggested CMV infection. Patient 12 had severe pneumonia and respiratory failure. Patient 6 expired at home 1 year after diagnosis and initiation of treatment; however, the cause of death could not be ascertained.
Visual outcome was good with complete restoration of visual acuity in five patients, while the remaining five patients (including two with IRIS) had severely impaired vision (visual acuity <6 of 60). All symptomatic patients had poor visual outcome, and all patients who were diagnosed on screening achieved normal vision (except patient 6).
The median follow-up period is 30 months (total follow-up is 625 patient months). None of the patients had recurrence of CMV disease.
D I S C U S S I O N
There is paucity of literature on paediatric HIV and CMV co-infection (Table 3) [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Retinitis was the most common manifestation of CMV disease in HIV-infected children in this series, and this has also been the experience of other workers in this field [8, 17, 19, [26] [27] [28] [29] . Unlike other major organ involvement because of CMV infection such as pneumonia and colitis, diagnosis of CMV retinitis is based only on typical fundus findings and laboratory confirmation is not required [30, 31] . The most common symptoms associated with CMV retinitis in adults include floaters of light and blurring of vision [32] . In our cohort, 40% children presented with blurring of vision. This figure is strikingly less as compared with a prevalence of 88% seen in one adult study [32] . All asymptomatic children (60%) were diagnosed on active screening. Screening is especially important in young children who may be unable to communicate effectively.
CMV involves gastrointestinal tract in <2% patients [29] . The most common manifestation is colitis [33] , and this is associated with high mortality [34] . Perforation develops in <10% patients [33] . One infant in our series developed CMV colitis with perforation peritonitis and succumbed to her illness.
The true prevalence of CMV pneumonia in HIVinfected children is not known, as they are usually co-infected with other organisms and histopathological confirmation of the diagnosis is often difficult. However, a few autopsy studies have shown pneumonia to be the most common CMV-associated disease [35] [36] [37] . In one study where isolation of CMV was attempted from bronchoalveolar lavage fluid, CMV was identified in 36% of the HIV-infected children. However, half of these patients were coinfected with other respiratory pathogens as well [38] . CMV pneumonia has been reported to be associated with a high mortality [38] . In our series, two children were presumed to have CMV pneumonia (one of them also had CMV colitis). Both patients were treated with ganciclovir but they succumbed to their illness.
IRIS is a potentially vision-threatening complication of CMV retinitis. Unmasking IRIS is relatively more common than paradoxical IRIS and may develop as early as 1 week or as late as few years after initiating ART [39] [40] [41] . Majority of the cases present within the first 3 months at a median duration of around 4 weeks [42] . In the absence of HIV viral load monitoring to document a log 10 fall from baseline, we used an increase in CD4þ T cell counts as an indicator of immune recovery [10, 11] . The prevalence of CMV IRIS in our cohort was 20%. This figure is similar to that reported in other series [9, 12, 17] . We could not identify any patient with paradoxical IRIS.
CD4þ T cell count <100 cells/ml has been defined as a risk factor for CMV retinitis in adults [20] . However, there are no such cut-offs available for children. We observed that majority of the children had CD4þ T cell <10% of total lymphocytes; however, it was >10% (14.9% and 18%) in two patients (without IRIS). All children with systemic involvement had CD4% <3%. Thus, it can be inferred that a routine eye screening must be done in all children with CD4% <20%. Moreover, another important factor that predisposes to CMV disease is late diagnosis of HIV infection as is often seen in India. The median age at diagnosis of CMV infection in our cohort was 6 years. Hence, it is important that a detailed screening for all opportunistic infections be done at the time of initial diagnosis.
The mainstay of treatment for CMV disease is intravenous ganciclovir (5 mg/kg/dose, twice daily) and the duration is determined by clinical response (minimum 2-3 weeks). Foscarnet can be used in patients with refractory CMV disease; however, it is expensive and is not easily available in several countries including India. Systemic therapy is better than local therapy alone for CMV retinitis, as it prevents dissemination of disease to the opposite eye and other visceral organs [43] . Addition of intravitreal therapy is considered in patients with more severe eye disease and involvement of central part of retina [12] . All children in the current study were treated with intravenous ganciclovir, and four patients were also given intravitreal therapy. One patient was also treated with foscarnet, but the vision could not be salvaged. Oral ganciclovir (5 mg/kg/day) is recommended for maintenance therapy and is continued till immune reconstitution occurs [44] [45] [46] [47] . All 10 patients who survived induction phase were initiated on maintenance therapy with ganciclovir. CMV prophylaxis was discontinued as per recommendations, and no patient had disease relapse on follow-up.
CMV IRIS is managed with antiviral therapy and sometimes systemic or local glucocorticoids. Aggressive treatment has been reported to improve vision outcome in adult series, but there is paucity of literature on children [9, [39] [40] [41] 48] . Systemic glucocorticoids were used in two patients as a desperate measure for vision-threatening inflammation; however, despite antiviral and anti-inflammatory therapy, the vision could not be salvaged. One patient had evidence of CMV retinitis at the time of ART failure (10 years after initiation of ART), thus implying the need for frequent monitoring especially in children with falling CD4 counts.
To conclude, CMV infection remains a significant problem in HIV-infected children despite the introduction of ART. We speculate that a good prognosis can only be achieved with early detection of CMV retinitis (the most common end-organ disease associated with CMV infection) by active screening and initiation of systemic ganciclovir. Once symptomatic (with or without IRIS), the visual prognosis is usually poor. Thus, all HIV-positive children must be screened for CMV retinitis at the time of their initial diagnosis. Intravenous ganciclovir is an effective and safe therapy for CMV retinitis in children (with occasional transient haematological side effects); however, for severe systemic disease, the therapy probably needs to be augmented using foscarnet.
